Afluria Quadrivalent (influenza vaccine) / CSL Behring - LARVOL DELTA

The Road to Readiness: Commentary on the Journey of a Zoonotic H5 Influenza Vaccine Strain Update. (PubMed, Vaccines (Basel)) - P2 | "To facilitate regulatory approval, the licence of an existing zoonotic vaccine, Aflunov (A/turkey/Turkey/01/2005)-a pre-pandemic monovalent A/H5N1 adjuvanted with MF59 and manufactured using the egg-based platform-was duplicated, with the plan to submit a variation to the duplicate licence for the strain update. In terms of procurement and logistics, early consultation between the European Commission and EU member states resulted in the award of a Framework Contract for the initial supply of 665,000 doses to 15 states. Learnings from the development of this vaccine may help to improve pandemic readiness in the future."

Journal • Review • Infectious Disease • Influenza • Respiratory Diseases

CSL Seqirus to Highlight Commitment to Influenza Protection with More than 20 Data Presentations at OPTIONS XI (CSL Behring Press Release) - "CSL Seqirus...announced new data will be presented at the Options for the Control of Influenza (OPTIONS XI) conference taking place September 26-29, 2022 in Belfast, United Kingdom. Data derived from a broad range of seasonal and pandemic influenza studies, including an oral presentation of influenza risk factors, will be shared....In addition, CSL Seqirus will host a symposium...on Monday, September 26, 2022, from 11:30-12:30 BST, highlighting the importance of influenza pandemic preparedness, the role of neuraminidase in influenza infection and the value of real-world evidence in public health decision making."

Clinical data • HEOR • Retrospective data • Infectious Disease • Influenza

New Data at OPTIONS XI Conference Highlight Burden of Seasonal Influenza on Health Systems and the Need for Increased Vaccination Rates (CSL Behring Press Release) - "CSL Seqirus...announced new data highlighting the significant burden influenza places on hospitals and healthcare resource use, as well as on more vulnerable populations such as children. The data are being presented in oral and poster sessions at OPTIONS for the Control of Influenza XI (OPTIONS XI), being held in Belfast, United Kingdom, from September 26-29, 2022."

Clinical data • Retrospective data • Infectious Disease • Influenza